Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

David F. McDermott, Mahrukh A. Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W Joseph, Sumanta K. Pal, James A. Reeves, Mario Sznol, John Hainsworth, W. Kimryn Rathmell, Walter M. Stadler, Thomas Hutson, Martin E. Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo DanielliViktor Gruenwald, Toni K. Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault-Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S. Chen, Priti S. Hegde, Christina Schiff, Gregg D. Fine, Thomas Powles

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients with treatment-naive metastatic renal cell carcinoma. Co-primary endpoints were progression-free survival (PFS) in intent-to-treat and PD-L1+ populations. Intent-to-treat PFS hazard ratios for atezolizumab + bevacizumab or atezolizumab monotherapy versus sunitinib were 1.0 (95% confidence interval (CI), 0.69-1.45) and 1.19 (95% CI, 0.82-1.71), respectively; PD-L1+ PFS hazard ratios were 0.64 (95% CI, 0.38-1.08) and 1.03 (95% CI, 0.63-1.67), respectively. Exploratory biomarker analyses indicated that tumor mutation and neoantigen burden were not associated with PFS. Angiogenesis, T-effector/IFN-γ response, and myeloid inflammatory gene expression signatures were strongly and differentially associated with PFS within and across the treatments. These molecular profiles suggest that prediction of outcomes with anti-VEGF and immunotherapy may be possible and offer mechanistic insights into how blocking VEGF may overcome resistance to immune checkpoint blockade.

Original languageEnglish (US)
Pages (from-to)749-757
Number of pages9
JournalNature Medicine
Volume24
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Disease-Free Survival
Cells
Confidence Intervals
Hazards
Biomarkers
Gene expression
Tumors
Transcriptome
Immunotherapy
Bevacizumab
MPDL3280A
sunitinib
Mutation
Therapeutics
Population
Neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. / McDermott, David F.; Huseni, Mahrukh A.; Atkins, Michael B.; Motzer, Robert J.; Rini, Brian I.; Escudier, Bernard; Fong, Lawrence; Joseph, Richard W; Pal, Sumanta K.; Reeves, James A.; Sznol, Mario; Hainsworth, John; Rathmell, W. Kimryn; Stadler, Walter M.; Hutson, Thomas; Gore, Martin E.; Ravaud, Alain; Bracarda, Sergio; Suárez, Cristina; Danielli, Riccardo; Gruenwald, Viktor; Choueiri, Toni K.; Nickles, Dorothee; Jhunjhunwala, Suchit; Piault-Louis, Elisabeth; Thobhani, Alpa; Qiu, Jiaheng; Chen, Daniel S.; Hegde, Priti S.; Schiff, Christina; Fine, Gregg D.; Powles, Thomas.

In: Nature Medicine, Vol. 24, No. 6, 01.06.2018, p. 749-757.

Research output: Contribution to journalArticle

McDermott, DF, Huseni, MA, Atkins, MB, Motzer, RJ, Rini, BI, Escudier, B, Fong, L, Joseph, RW, Pal, SK, Reeves, JA, Sznol, M, Hainsworth, J, Rathmell, WK, Stadler, WM, Hutson, T, Gore, ME, Ravaud, A, Bracarda, S, Suárez, C, Danielli, R, Gruenwald, V, Choueiri, TK, Nickles, D, Jhunjhunwala, S, Piault-Louis, E, Thobhani, A, Qiu, J, Chen, DS, Hegde, PS, Schiff, C, Fine, GD & Powles, T 2018, 'Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma', Nature Medicine, vol. 24, no. 6, pp. 749-757. https://doi.org/10.1038/s41591-018-0053-3
McDermott, David F. ; Huseni, Mahrukh A. ; Atkins, Michael B. ; Motzer, Robert J. ; Rini, Brian I. ; Escudier, Bernard ; Fong, Lawrence ; Joseph, Richard W ; Pal, Sumanta K. ; Reeves, James A. ; Sznol, Mario ; Hainsworth, John ; Rathmell, W. Kimryn ; Stadler, Walter M. ; Hutson, Thomas ; Gore, Martin E. ; Ravaud, Alain ; Bracarda, Sergio ; Suárez, Cristina ; Danielli, Riccardo ; Gruenwald, Viktor ; Choueiri, Toni K. ; Nickles, Dorothee ; Jhunjhunwala, Suchit ; Piault-Louis, Elisabeth ; Thobhani, Alpa ; Qiu, Jiaheng ; Chen, Daniel S. ; Hegde, Priti S. ; Schiff, Christina ; Fine, Gregg D. ; Powles, Thomas. / Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. In: Nature Medicine. 2018 ; Vol. 24, No. 6. pp. 749-757.
@article{8f277ee1651f4074a442a28cf30ad893,
title = "Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma",
abstract = "We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients with treatment-naive metastatic renal cell carcinoma. Co-primary endpoints were progression-free survival (PFS) in intent-to-treat and PD-L1+ populations. Intent-to-treat PFS hazard ratios for atezolizumab + bevacizumab or atezolizumab monotherapy versus sunitinib were 1.0 (95{\%} confidence interval (CI), 0.69-1.45) and 1.19 (95{\%} CI, 0.82-1.71), respectively; PD-L1+ PFS hazard ratios were 0.64 (95{\%} CI, 0.38-1.08) and 1.03 (95{\%} CI, 0.63-1.67), respectively. Exploratory biomarker analyses indicated that tumor mutation and neoantigen burden were not associated with PFS. Angiogenesis, T-effector/IFN-γ response, and myeloid inflammatory gene expression signatures were strongly and differentially associated with PFS within and across the treatments. These molecular profiles suggest that prediction of outcomes with anti-VEGF and immunotherapy may be possible and offer mechanistic insights into how blocking VEGF may overcome resistance to immune checkpoint blockade.",
author = "McDermott, {David F.} and Huseni, {Mahrukh A.} and Atkins, {Michael B.} and Motzer, {Robert J.} and Rini, {Brian I.} and Bernard Escudier and Lawrence Fong and Joseph, {Richard W} and Pal, {Sumanta K.} and Reeves, {James A.} and Mario Sznol and John Hainsworth and Rathmell, {W. Kimryn} and Stadler, {Walter M.} and Thomas Hutson and Gore, {Martin E.} and Alain Ravaud and Sergio Bracarda and Cristina Su{\'a}rez and Riccardo Danielli and Viktor Gruenwald and Choueiri, {Toni K.} and Dorothee Nickles and Suchit Jhunjhunwala and Elisabeth Piault-Louis and Alpa Thobhani and Jiaheng Qiu and Chen, {Daniel S.} and Hegde, {Priti S.} and Christina Schiff and Fine, {Gregg D.} and Thomas Powles",
year = "2018",
month = "6",
day = "1",
doi = "10.1038/s41591-018-0053-3",
language = "English (US)",
volume = "24",
pages = "749--757",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

AU - McDermott, David F.

AU - Huseni, Mahrukh A.

AU - Atkins, Michael B.

AU - Motzer, Robert J.

AU - Rini, Brian I.

AU - Escudier, Bernard

AU - Fong, Lawrence

AU - Joseph, Richard W

AU - Pal, Sumanta K.

AU - Reeves, James A.

AU - Sznol, Mario

AU - Hainsworth, John

AU - Rathmell, W. Kimryn

AU - Stadler, Walter M.

AU - Hutson, Thomas

AU - Gore, Martin E.

AU - Ravaud, Alain

AU - Bracarda, Sergio

AU - Suárez, Cristina

AU - Danielli, Riccardo

AU - Gruenwald, Viktor

AU - Choueiri, Toni K.

AU - Nickles, Dorothee

AU - Jhunjhunwala, Suchit

AU - Piault-Louis, Elisabeth

AU - Thobhani, Alpa

AU - Qiu, Jiaheng

AU - Chen, Daniel S.

AU - Hegde, Priti S.

AU - Schiff, Christina

AU - Fine, Gregg D.

AU - Powles, Thomas

PY - 2018/6/1

Y1 - 2018/6/1

N2 - We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients with treatment-naive metastatic renal cell carcinoma. Co-primary endpoints were progression-free survival (PFS) in intent-to-treat and PD-L1+ populations. Intent-to-treat PFS hazard ratios for atezolizumab + bevacizumab or atezolizumab monotherapy versus sunitinib were 1.0 (95% confidence interval (CI), 0.69-1.45) and 1.19 (95% CI, 0.82-1.71), respectively; PD-L1+ PFS hazard ratios were 0.64 (95% CI, 0.38-1.08) and 1.03 (95% CI, 0.63-1.67), respectively. Exploratory biomarker analyses indicated that tumor mutation and neoantigen burden were not associated with PFS. Angiogenesis, T-effector/IFN-γ response, and myeloid inflammatory gene expression signatures were strongly and differentially associated with PFS within and across the treatments. These molecular profiles suggest that prediction of outcomes with anti-VEGF and immunotherapy may be possible and offer mechanistic insights into how blocking VEGF may overcome resistance to immune checkpoint blockade.

AB - We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients with treatment-naive metastatic renal cell carcinoma. Co-primary endpoints were progression-free survival (PFS) in intent-to-treat and PD-L1+ populations. Intent-to-treat PFS hazard ratios for atezolizumab + bevacizumab or atezolizumab monotherapy versus sunitinib were 1.0 (95% confidence interval (CI), 0.69-1.45) and 1.19 (95% CI, 0.82-1.71), respectively; PD-L1+ PFS hazard ratios were 0.64 (95% CI, 0.38-1.08) and 1.03 (95% CI, 0.63-1.67), respectively. Exploratory biomarker analyses indicated that tumor mutation and neoantigen burden were not associated with PFS. Angiogenesis, T-effector/IFN-γ response, and myeloid inflammatory gene expression signatures were strongly and differentially associated with PFS within and across the treatments. These molecular profiles suggest that prediction of outcomes with anti-VEGF and immunotherapy may be possible and offer mechanistic insights into how blocking VEGF may overcome resistance to immune checkpoint blockade.

UR - http://www.scopus.com/inward/record.url?scp=85048001150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048001150&partnerID=8YFLogxK

U2 - 10.1038/s41591-018-0053-3

DO - 10.1038/s41591-018-0053-3

M3 - Article

C2 - 29867230

AN - SCOPUS:85048001150

VL - 24

SP - 749

EP - 757

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 6

ER -